Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 7/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 3/20 | 0.55 |
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CA9 | Q16790 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.47 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.47 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.47 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1647661 | 1.00 | PYGB (0.58) | PYGBGAACA12CA1CA2 | |
| SCHEMBL1647658 | 1.00 | PYGB (0.58) | PYGBGAACA12CA1CA2 | |
| SCHEMBL19538490 | 1.00 | PYGB (0.58) | PYGBGAACA12CA1CA2 | |
| SCHEMBL14707760 | 1.00 | PYGB (0.58) | PYGBGAACA12CA1CA2 | |
| SCHEMBL3228008 | 1.00 | PYGB (0.58) | PYGBGAACA12CA1CA2 | |
| SCHEMBL12038703 | 1.00 | PYGB (0.58) | PYGBGAACA12CA1CA2 | |
| SCHEMBL9650344 | 0.98 | PYGB (0.55) | PYGBGAACA12CA1CA2 | |
| SCHEMBL8059606 | 0.98 | PYGB (0.55) | PYGBGAACA12CA1CA2 | |
| SCHEMBL23430833 | 0.82 | LGALS8 (0.53) | PYGBCA12CA1CA2CA9 | |
| SCHEMBL21894588 | 0.82 | LGALS8 (0.53) | PYGBCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170313661-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2017-11-02 | — | — | US | disclosed |
| US-9617221-B2 | Kinase modulators for the treatment of cancer | SYNOVO GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313661-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | MAP3K10, MAP3K12, MAP3K20 | PYGB 3168/4885GAA 2734/4885CA12 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.